lebrikizumab,cbp-201,rpt193,nemolizumab,etrasimod,cendakimab,amlitelimab sar445229,aslan004,tralokinumab
rapt therapeutics,amgen,pfizer,bms,galderma,eli lilly,sanofi,connect biopharma,aslan pharmaceuticals,astrazeneca,
['cbp201', 'amlitelimab', 'cendakimab', 'etrasimod ', 'lebri,(-celebri)', 'rpt193', 'nemolizumab', 'derm', 'aslan ', 'connect bio', 'galderma', 'kymab', 'bms', 'sanofi', 'dermira', 'amgen', ' lilly', 'pfizer']
the therapeutic drought is finally ending. hot topics atopic dermatitis, new developments: what s in the pipeline for patients? + can the translational revolution in ad also extend to alopecia areata? explored by at #aad2023 
Official Twitter account for the Department of Dermatology @mountsinainyc. Leaders in dermatological treatment, care, research and education.